Alkermes Orexin Agonist Shows Early Promise in ADHD

Alkermes said its experimental orexin agonist showed potential to treat people with ADHD in an early-stage study, according to STAT News. It is the first time this class of drugs has signaled promise against the condition.

Orexin agonists work on brain signaling tied to wakefulness and arousal. Until now, drugmakers have chased them mainly for sleep disorders such as narcolepsy, where boosting orexin activity helps patients stay awake. Applying the same mechanism to ADHD is a new direction, and a positive early readout suggests the pathway may influence attention and focus, not just sleep.

The practical stakes are large. ADHD treatment still leans heavily on stimulants like Adderall and Ritalin, which carry abuse potential and supply shortages. A non-stimulant option with a novel mechanism could reshape prescribing if later trials hold up. Early-stage results are preliminary, and Alkermes will need larger, controlled studies to confirm the effect and define safety before the therapy nears approval.